Successful immunosuppressive therapy for a child with Myelodysplastic syndrome

✍ Scribed by Orimoto, Mizue ;Maeda, Miho ;Cai, Ling-zhi ;Hayakawa, Jun ;Ueda, Takahiro ;Migita, Makoto ;Asano, Takeshi

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 66 KB
• Volume: 40
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.10228

✦ Synopsis

chemotherapeutic regimen is unknown but commonly prescribed drugs include vincristine, doxorubicin and cyclophosphamide [1,[3][4][5]10]. Simple observation of small, accessible, solitary lesions in clinically well infants has been recommended in the absence of adverse prognostic features. These include the Kasabach-Merritt syndrome, multi focality, and the presence of histopathologic or ultrastructural appearances suggestive of composite myofibromatosis. Identification of angiogenesis factors such as bFGF and VEGF may help to distinguish HPC from other vascular tumours such as haemangiomas [1,5,7]. As there are no definite clinical or histologic criteria to predict which tumours will spontaneously regress, complete or non-mutilating surgical excision is the preferred treatment. Lesions arising in subcutaneous tissues in the lower limbs lend themselves to this approach [1,5,7]. Irrespective of which treatment policy is adopted, long term follow up is recommended as relapses may occur late [1,[3][4][5]11].